- NCIt
- C8101
Loading cancer entity…
Loading cancer entity…
Clinical trials
1,164 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06586957 | A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 238 | NiKang Therapeutics, Inc.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04981119 | Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing(BASECAMP-1) | recruiting | — | 500 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Sep 25, 2026 |
| NCT06218914 | Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors | recruiting | Phase 1 | 108 | AstraZenecaINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06788509 | A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring | enrolling by invitation | Phase 1 | 120 | Janssen Research & Development, LLCINDUSTRY | 15 | Sep 25, 2026 | clinicaltrials |
| NCT02293954 | Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer | active not recruiting | N/A | 20 | City of Hope Medical CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06088004 | Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 218 | Suzhou Abogen Biosciences Co., Ltd.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06915753 | Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations(SURF431) | recruiting | Phase 1 | 125 | Tyra Biosciences, IncINDUSTRY | 4 | Sep 23, 2026 | clinicaltrials |
| NCT07228247 | A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors | recruiting | Phase 1 / Phase 2 | 147 | HutchmedINDUSTRY | 2 | Sep 22, 2026 | clinicaltrials |
| NCT06088472 | TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors | active not recruiting | Phase 1 | 12 | Grit BiotechnologyINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06398418 | R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors | recruiting | Phase 1 | 33 | Rise Therapeutics LLCINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07396584 | HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor | recruiting | Phase 1 / Phase 2 | 186 | HutchmedINDUSTRY | 2 | Sep 18, 2026 | clinicaltrials |
| NCT02974738 | A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) | active not recruiting | Phase 1 | 120 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 0 | Sep 16, 2026 | clinicaltrials |
| NCT04165772 | Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors | recruiting | Phase 2 | 212 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05430373 | GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors | recruiting | Phase 1 | 31 | Grit BiotechnologyINDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01375829 | Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | active not recruiting | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04739696 | Developing a Virtual Stress Management Intervention for Spousal/Partnered Caregivers of Solid Tumor Cancer Patients.(eCare) | active not recruiting | N/A | 538 | University of Colorado, DenverOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06292845 | Ex Vivo Tumor Visualization and Resection Margin Assessment Using Topically Applied Fluorescent Imaging Agents(SprayDye) | recruiting | N/A | 200 | Erasmus Medical CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07225088 | DESCANSO, a Mental Health Intervention for Depression, Insomnia, and Fatigue Symptoms in Latino People With Cancer | recruiting | N/A | 125 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06625775 | Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 392 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)INDUSTRY | 6 | Sep 9, 2026 | clinicaltrials |
| NCT00878163 | GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery | active not recruiting | Phase 1 | 55 | National Cancer Institute (NCI)NIH | 1 | Sep 8, 2026 | clinicaltrials |
| NCT04015609 | Psychotherapy Intervention for Latinos With Advanced Cancer | recruiting | N/A | 177 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Sep 8, 2026 | clinicaltrials |
| NCT04537936 | Psychotherapy Intervention for Latinos With Adv Cancer | recruiting | N/A | 117 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Sep 8, 2026 | clinicaltrials |
| NCT04243499 | First-in-Human Study of ICT01 in Patients With Advanced Cancer(EVICTION) | active not recruiting | Phase 1 / Phase 2 | 293 | ImCheck Therapeutics, an Ipsen companyINDUSTRY | 6 | Sep 4, 2026 | clinicaltrials |
| NCT07361562 | A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 100 | Cogent Biosciences, Inc.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06337084 | Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors | active not recruiting | Phase 1 | 12 | Monopar TherapeuticsINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06617169 | Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors | active not recruiting | Phase 1 | 12 | Monopar TherapeuticsINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04913285 | A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors | recruiting | Phase 1 | 400 | Pierre Fabre MedicamentINDUSTRY | 7 | Sep 2, 2026 | clinicaltrials |
| NCT05868226 | PRE-ISPY Phase I/II Oncology Platform Program(PRE-ISPY) | recruiting | Phase 1 / Phase 2 | 280 | QuantumLeap Healthcare CollaborativeOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06507306 | A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies | active not recruiting | Phase 1 | 92 | Kumquat Biosciences Inc.INDUSTRY | 4 | Sep 2, 2026 | clinicaltrials |
| NCT05958121 | IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors | recruiting | Phase 1 / Phase 2 | 400 | Immatics Biotechnologies GmbHINDUSTRY | 2 | Sep 1, 2026 | clinicaltrials |
| NCT06462794 | First In Human Study of CX-801 in Advanced Solid Tumors | recruiting | Phase 1 | 121 | CytomX TherapeuticsINDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07383506 | A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 90 | Cogent Biosciences, Inc.INDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)(STARTRK-2) | active not recruiting | Phase 2 | 534 | Hoffmann-La RocheINDUSTRY | 16 | Aug 25, 2026 | clinicaltrials |
| NCT04725474 | First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)(GDFATHER) | active not recruiting | Phase 1 / Phase 2 | 199 | CatalYm GmbHINDUSTRY | 3 | Aug 19, 2026 | clinicaltrials |
| NCT07246863 | Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC | recruiting | Phase 2 | 131 | CatalYm GmbHINDUSTRY | 7 | Aug 19, 2026 | clinicaltrials |
| NCT04928508 | Advanced or Recurrent Solid Tumors Treated With SHetA2(Okgyn1) | active not recruiting | Phase 1 | 50 | University of OklahomaOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT00045201 | Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07139990 | Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)(PRISM) | recruiting | Phase 1 | 105 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT02290522 | Copenhagen Prospective Personalized Oncology (CoPPO)(CoPPO) | recruiting | N/A | 500 | Ulrik LassenOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT00935090 | 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer | active not recruiting | — | — | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07098988 | Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC | recruiting | Phase 2 | 107 | CatalYm GmbHINDUSTRY | 7 | Aug 10, 2026 | clinicaltrials |
| NCT06506643 | Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms | recruiting | Phase 1 / Phase 2 | 36 | Vector Vitale LLCINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07256756 | A Study of GC203 TIL in Advanced Solid Tumors (NF) | recruiting | Phase 1 | 8 | Shanghai Juncell TherapeuticsINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07294872 | A Study of TIL in Advanced Solid Tumors (CZ) | not yet recruiting | Phase 1 | 30 | Shanghai Juncell TherapeuticsINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06380660 | Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 298 | Acerand Therapeutics (Shanghai) LimitedINDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT03915678 | Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors(AGADIR) | active not recruiting | Phase 2 | 247 | Institut BergoniéOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07718581 | HMPL-A830 in Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 147 | HutchmedINDUSTRY | 1 | Jul 22, 2026 | clinicaltrials |
| NCT00992303 | Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants | recruiting | — | 10,000 | University of Texas Southwestern Medical CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06265688 | First In Human Study of CX-2051 in Advanced Solid Tumors | recruiting | Phase 1 | 160 | CytomX TherapeuticsINDUSTRY | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07487805 | Ivermectin Combined With Immune Checkpoint Inhibition in Cancer (ICONIC)(ICONIC) | not yet recruiting | Phase 2 | 80 | University of FloridaOTHER | 0 | Jul 15, 2026 | clinicaltrials |
Data updated 2 days agoSource updated Sep 28, 2026source: clinicaltrials